Natalie Ertz-Archambault1, Heidi Kosiorek2, Gretchen E Taylor1, Katalin Kelemen3, Amylou Dueck2, Janna Castro4, Robert Marino5, Susanne Gauthier5, Laura Finn6, Lisa Z Sproat7, Jeanne Palmer7, Ruben A Mesa7, Aref Al-Kali6, James Foran8, Raoul Tibes7. 1. Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona. 2. Division of Health Sciences Research, Section of Biostatistics, Mayo Clinic, Phoenix, Arizona. 3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, Arizona. 4. Department of Information Technology, Mayo Clinic, Phoenix, Arizona. 5. Division of Planning and Practice Analysis, Mayo Clinic, Phoenix, Arizona. 6. Department of Hematology and Oncology, Mayo Clinic, Rochester, Minnesota. 7. Department of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona. 8. Department of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida.
Abstract
IMPORTANCE: Therapy-related myeloid neoplasms are a potentially life-threatening consequence of treatment for autoimmune disease (AID) and an emerging clinical phenomenon. OBJECTIVE: To query the association of cytotoxic, anti-inflammatory, and immunomodulating agents to treat patients with AID with the risk for developing myeloid neoplasm. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case-control study and medical record review included 40 011 patients with an International Classification of Diseases, Ninth Revision, coded diagnosis of primary AID who were seen at 2 centers from January 1, 2004, to December 31, 2014; of these, 311 patients had a concomitant coded diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Eighty-six cases met strict inclusion criteria. A case-control match was performed at a 2:1 ratio. MAIN OUTCOMES AND MEASURES: Odds ratio (OR) assessment for AID-directed therapies. RESULTS: Among the 86 patients who met inclusion criteria (49 men [57%]; 37 women [43%]; mean [SD] age, 72.3 [15.6] years), 55 (64.0%) had MDS, 21 (24.4%) had de novo AML, and 10 (11.6%) had AML and a history of MDS. Rheumatoid arthritis (23 [26.7%]), psoriasis (18 [20.9%]), and systemic lupus erythematosus (12 [14.0%]) were the most common autoimmune profiles. Median time from onset of AID to diagnosis of myeloid neoplasm was 8 (interquartile range, 4-15) years. A total of 57 of 86 cases (66.3%) received a cytotoxic or an immunomodulating agent. In the comparison group of 172 controls (98 men [57.0%]; 74 women [43.0%]; mean [SD] age, 72.7 [13.8] years), 105 (61.0%) received either agent (P = .50). Azathioprine sodium use was observed more frequently in cases (odds ratio [OR], 7.05; 95% CI, 2.35- 21.13; P < .001). Notable but insignificant case cohort use among cytotoxic agents was found for exposure to cyclophosphamide (OR, 3.58; 95% CI, 0.91-14.11) followed by mitoxantrone hydrochloride (OR, 2.73; 95% CI, 0.23-33.0). Methotrexate sodium (OR, 0.60; 95% CI, 0.29-1.22), mercaptopurine (OR, 0.62; 95% CI, 0.15-2.53), and mycophenolate mofetil hydrochloride (OR, 0.66; 95% CI, 0.21-2.03) had favorable ORs that were not statistically significant. No significant association between a specific length of time of exposure to an agent and the drug's category was observed. CONCLUSIONS AND RELEVANCE: In a large population with primary AID, azathioprine exposure was associated with a 7-fold risk for myeloid neoplasm. The control and case cohorts had similar systemic exposures by agent category. No association was found for anti-tumor necrosis factor agents. Finally, no timeline was found for the association of drug exposure with the incidence in development of myeloid neoplasm.
IMPORTANCE: Therapy-related myeloid neoplasms are a potentially life-threatening consequence of treatment for autoimmune disease (AID) and an emerging clinical phenomenon. OBJECTIVE: To query the association of cytotoxic, anti-inflammatory, and immunomodulating agents to treat patients with AID with the risk for developing myeloid neoplasm. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case-control study and medical record review included 40 011 patients with an International Classification of Diseases, Ninth Revision, coded diagnosis of primary AID who were seen at 2 centers from January 1, 2004, to December 31, 2014; of these, 311 patients had a concomitant coded diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Eighty-six cases met strict inclusion criteria. A case-control match was performed at a 2:1 ratio. MAIN OUTCOMES AND MEASURES: Odds ratio (OR) assessment for AID-directed therapies. RESULTS: Among the 86 patients who met inclusion criteria (49 men [57%]; 37 women [43%]; mean [SD] age, 72.3 [15.6] years), 55 (64.0%) had MDS, 21 (24.4%) had de novo AML, and 10 (11.6%) had AML and a history of MDS. Rheumatoid arthritis (23 [26.7%]), psoriasis (18 [20.9%]), and systemic lupus erythematosus (12 [14.0%]) were the most common autoimmune profiles. Median time from onset of AID to diagnosis of myeloid neoplasm was 8 (interquartile range, 4-15) years. A total of 57 of 86 cases (66.3%) received a cytotoxic or an immunomodulating agent. In the comparison group of 172 controls (98 men [57.0%]; 74 women [43.0%]; mean [SD] age, 72.7 [13.8] years), 105 (61.0%) received either agent (P = .50). Azathioprine sodium use was observed more frequently in cases (odds ratio [OR], 7.05; 95% CI, 2.35- 21.13; P < .001). Notable but insignificant case cohort use among cytotoxic agents was found for exposure to cyclophosphamide (OR, 3.58; 95% CI, 0.91-14.11) followed by mitoxantrone hydrochloride (OR, 2.73; 95% CI, 0.23-33.0). Methotrexate sodium (OR, 0.60; 95% CI, 0.29-1.22), mercaptopurine (OR, 0.62; 95% CI, 0.15-2.53), and mycophenolate mofetil hydrochloride (OR, 0.66; 95% CI, 0.21-2.03) had favorable ORs that were not statistically significant. No significant association between a specific length of time of exposure to an agent and the drug's category was observed. CONCLUSIONS AND RELEVANCE: In a large population with primary AID, azathioprine exposure was associated with a 7-fold risk for myeloid neoplasm. The control and case cohorts had similar systemic exposures by agent category. No association was found for anti-tumor necrosis factor agents. Finally, no timeline was found for the association of drug exposure with the incidence in development of myeloid neoplasm.
Authors: Bart L Scott; Aravind Ramakrishnan; Mark Fosdal; Barry Storer; Pamela Becker; Steve Petersdorf; H Joachim Deeg Journal: Br J Haematol Date: 2010-03-16 Impact factor: 6.998
Authors: Leena Chaudhuri; Nicole D Vincelette; Brian D Koh; Ryan M Naylor; Karen S Flatten; Kevin L Peterson; Amanda McNally; Ivana Gojo; Judith E Karp; Ruben A Mesa; Lisa O Sproat; James M Bogenberger; Scott H Kaufmann; Raoul Tibes Journal: Haematologica Date: 2013-10-31 Impact factor: 9.941
Authors: Moshe C Ornstein; Sudipto Mukherjee; Sanjay Mohan; Paul Elson; Ramon V Tiu; Yogenthiran Saunthararajah; Cassie Kendeigh; Anjali Advani; Matt Kalaycio; Jaroslaw P Maciejewski; Mikkael A Sekeres Journal: Am J Hematol Date: 2013-11-21 Impact factor: 10.047
Authors: Raoul Tibes; James M Bogenberger; Leena Chaudhuri; R Tanner Hagelstrom; Donald Chow; Megan E Buechel; Irma M Gonzales; Tim Demuth; James Slack; Ruben A Mesa; Esteban Braggio; Hongwei H Yin; Shilpi Arora; David O Azorsa Journal: Blood Date: 2012-01-20 Impact factor: 22.113
Authors: P Geborek; A Bladström; C Turesson; A Gulfe; I F Petersson; T Saxne; H Olsson; L T H Jacobsson Journal: Ann Rheum Dis Date: 2005-02-04 Impact factor: 19.103
Authors: Bart L Scott; Aravind Ramakrishnan; Barry Storer; Pamela S Becker; Steve Petersdorf; Elihu H Estey; H Joachim Deeg Journal: Br J Haematol Date: 2010-01-07 Impact factor: 6.998
Authors: Kylee Maclachlan; Benjamin Diamond; Francesco Maura; Jens Hillengass; Ingemar Turesson; C Ola Landgren; Dickran Kazandjian Journal: Best Pract Res Clin Haematol Date: 2020-01-11 Impact factor: 3.020
Authors: Fatima Alnaimat; Khaled Al Oweidat; Anas Alrwashdeh; Ahmad Alnashrati; Saba Barham; Mohammad Hijaz; Dina Murad; Sameeha Alshelleh; Nathir Obeidat Journal: Arch Rheumatol Date: 2020-02-07 Impact factor: 1.472
Authors: Amy M Linabery; Michelle A Roesler; Michaela Richardson; Erica D Warlick; Phuong L Nguyen; Adina M Cioc; Jenny N Poynter Journal: Cancer Epidemiol Date: 2022-01-05 Impact factor: 2.984